30 completed, 16 terminated, 11 unknown, 8 withdrawn. 68 Phase 2, 14 Phase 1, 14 Phase 3.
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age mRNA-1283, mRNA-1273 - SARS-CoV-2 | Phase 2 | Recruiting | ModernaTX, Inc. | 300 | 2026-09-04 | 2026-10-29 |
| A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B - Influenza, SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 1320 | 2025-03-07 | 2025-10-20 |
| ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19) ACE2 Chewing Gum, Placebo Chewing Gum - SARS-CoV-2 | Phase 1 / Phase 2 | Withdrawn | University of Pennsylvania | 2025-02-01 | 2025-03-30 | |
| SARS-CoV-2 Safety Study for the Treatment of COVID-19 HIV, Malignant Neoplasms Safety Study for the Treatment of Neoplasms - SARS-CoV-2 | Phase 2 | Withdrawn | DHA Coffee Co., Ltd | 2025-01-28 | 2025-09-04 | |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) Placebo comparator, PRS CK STORM - SARS-CoV-2, Influenza, Human | Phase 1 / Phase 2 | Recruiting | PEACHES BIOTECH | 50 | 2024-10-02 | 2026-06-10 |
| A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) mRNA-1083 - Influenza, SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 931 | 2024-07-15 | 2026-10-08 |
| PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 Upamostat, Placebo (PO) - SARS-CoV-2 | Phase 2 | Completed | Henry M. Jackson Foundation for the Advancement of Military Medicine | 92 | 2024-01-29 | 2026-04-17 |
| A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) SARS-CoV-2 Bivalent mRNA Vaccine, Saline - SARS-CoV-2 | Phase 2 | Unknown | AIM Vaccine Co., Ltd. | 450 | 2023-10-09 | 2023-11-24 |
| A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose) - SARS-CoV-2, COVID-19 | Phase 2 | Completed | GlaxoSmithKline | 692 | 2023-08-01 | 2025-10-23 |
| A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression Tafenoquine Oral Tablet, Placebo - COVID 19 Disease, Mild to Moderate COVID 19 Disease | Phase 2 | Unknown | 60P Australia Pty Ltd | 148 | 2023-08-01 | 2023-07-17 |
| A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 1758 | 2023-04-14 | 2025-12-23 |
| Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants mRNA-1273.214, Placebo - SARS-CoV-2 | Phase 2 | Terminated | ModernaTX, Inc. | 68 | 2022-09-30 | 2025-11-26 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old mRNA-1073, mRNA-1010, mRNA-1273 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 550 | 2022-05-13 | 2024-02-28 |
| Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People SARS-CoV-2 (LVRNA009) 50μg group, SARS-CoV-2 (LVRNA009) 100μg group, Placebo - SARS-CoV-2 | Phase 2 | Completed | AIM Vaccine Co., Ltd. | 420 | 2022-03-16 | 2023-09-06 |
| High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients mRNA-1273 (Moderna COVID-19 vaccine) - Lung Transplant Recipient, SARS-CoV-2 | Phase 1 / Phase 2 | Terminated | University of California, Los Angeles | 19 | 2022-03-10 | 2025-03-26 |
| A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 mRNA-1273.529, mRNA-1273, mRNA-1273.214 - SARS-CoV-2 | Phase 2 / Phase 3 | Completed | ModernaTX, Inc. | 3548 | 2022-02-16 | 2024-08-09 |
| A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults RBMRNA-176, Placebo - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | Argorna Pharmaceuticals Co., LTD | 480 | 2022-01-08 | 2024-01-10 |
| Convalescent Plasma Therapy for Hospitalized Patients With COVID-19 Convalescent plasma, Standard of care - COVID-19, Convalescent Plasma | Phase 2 | Completed | Tânia Portella Costa | 38 | 2022-01-06 | 2023-11-29 |
| Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial Angiotensin 1-7, Placebos - Coronavirus, Respiratory Failure | Phase 2 / Phase 3 | Unknown | Erasme University Hospital | 60 | 2021-12-30 | 2021-08-02 |
| A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters mRNA-1283, mRNA-1283.211, mRNA-1273 - SARS-CoV-2 | Phase 2 | Completed | ModernaTX, Inc. | 540 | 2021-12-06 | 2025-07-17 |
Showing 20 of 68. Sign in to see all of them.
COVID-19 (47) · Coronavirus Infections (22) · Virus Diseases (8) · Influenza, Human (5) · Respiratory Distress Syndrome (4) · Cytokine Release Syndrome (3) · Pneumonia (3) · Severe Acute Respiratory Syndrome (3) · Respiratory Insufficiency (2) · Cardiovascular Diseases (1) · Communicable Diseases (1) · Dyspnea (1) · Heart Failure (1) · Hypoxia (1) · Lung Diseases (1)
Infections (52) · RNA Virus Infections (51) · Respiratory Tract Diseases (51) · Respiratory Tract Infections (50) · Coronaviridae Infections (49) · Nidovirales Infections (49) · Lung Diseases (47) · Pneumonia, Viral (46) · Pneumonia (44) · Virus Diseases (43) · Coronavirus Infections (27) · Orthomyxoviridae Infections (5) · Pathological Conditions, Signs and Symptoms (5) · Respiration Disorders (5) · Pathologic Processes (4)
2019-nCoV Vaccine mRNA-1273 (8) · Hydroxychloroquine (8) · Saline Solution (4) · Standard of Care (4) · mRNA-1273.214 COVID-19 vaccine (4) · Azithromycin (3) · Sodium Chloride (3) · Ascorbic Acid (2) · CVnCoV COVID-19 vaccine (2) · ChAdOx1 nCoV-19 (2) · favipiravir (2) · Abatacept (1) · BNT162 Vaccine (1) · Baiya SARS-CoV-2 VAX COVID-19 vaccine (1) · COVID-19 Vaccines (1)
ModernaTX, Inc. (12) · AIM Vaccine Co., Ltd. (2) · Arcturus Therapeutics, Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · CureVac (2) · Genexine, Inc. (2) · University of Washington (2) · 60P Australia Pty Ltd (1) · Appili Therapeutics Inc. (1) · Argorna Pharmaceuticals Co., LTD (1) · AstraZeneca (1) · Bahçeşehir University (1) · BioNTech SE (1) · Blade Therapeutics (1) · Bristol-Myers Squibb (1)
United States (32) · China (5) · Brazil (4) · Canada (4) · Dominican Republic (3) · Mexico (3) · Panama (3) · Peru (3) · South Africa (3) · South Korea (3) · United Kingdom (3) · Argentina (2) · France (2) · Italy (2) · Puerto Rico (2)
JungWon Woo, Ph.D. (2) · Allison J McGeer, MD (1) · Arthur M Feldman, MD, PhD (1) · Bin DU, Prof. (1) · Christine Johnston, MD, MPH (1) · David Bernal, Dr. (1) · Emanuele Nicastri, MD (1) · Fan Zhang (1) · Filippo Annoni, MD (1) · Genovefa Papanicolaou, MD (1) · Gerry Gin Wai Kwok, MBBS (1) · Giovanni Martinelli, Prof. (1)
PMID 32788708, PMID 34473343, PMID 21366476, PMID 30519584, PMID 32382733, PMID 32493478, PMID 32736597, PMID 32771034, PMID 33066761, PMID 33189161, PMID 33215063, PMID 33284679, PMID 33333292, PMID 33568226, PMID 33681731, PMID 33707061, PMID 33820486, PMID 33935163, PMID 34379915, PMID 34407441, PMID 34526698, PMID 34826381, PMID 34870630, PMID 35045888, PMID 35101449, PMID 35156068, PMID 35191746, PMID 35241844, PMID 35291289, PMID 35454123, PMID 35544369, PMID 35604806, PMID 35668841, PMID 35713300, PMID 35713893, PMID 36112399, PMID 36120090, PMID 36202997, PMID 36238717, PMID 36260859, PMID 36314106, PMID 36348276, PMID 36376733, PMID 36458916, PMID 36474100, PMID 37348519, PMID 37653342, PMID 37703353, PMID 37783221, PMID 38518789
2023 (2)